Global Hydroxyethyl Starch Market Size By Type (HES 130/0.4, HES 200/0.5), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Hydroxyethyl Starch (HES) Market was valued at USD 505 million in 2023 and is projected to reach USD 792 million by 2031, growing at a CAGR of 5.8% during the forecast period (2023–2031). HES is a synthetic colloid solution used primarily in volume expansion therapies, especially during surgeries and trauma cases. The market is influenced by the rising demand for effective plasma expanders, increasing surgical procedures globally, and advancements in medical technologies. Moreover, the growing incidence of trauma, sepsis, and hypovolemia-related conditions is further fueling the market demand.

Drivers:

1. Rising Number of Surgeries and Trauma Cases:

With an increasing number of surgeries worldwide—especially cardiac, orthopedic, and general procedures—there is a parallel growth in demand for plasma expanders like hydroxyethyl starch.

2. Growing Demand for Volume Expanders in Critical Care:

In emergency and critical care settings, rapid volume replacement is essential. HES is commonly preferred due to its ability to quickly restore blood volume and maintain hemodynamic stability.

3. Technological Advancements in Formulations:

Continuous innovations in HES formulations to improve safety, biocompatibility, and efficiency are making these solutions more reliable and desirable for clinical use.

Restraints:

1. Regulatory Scrutiny and Product Withdrawals:

Several concerns regarding renal safety and coagulopathy have led to stricter regulatory guidelines in the US and Europe, limiting the use of certain HES products.

2. Availability of Safer Alternatives:

The availability of safer alternatives such as albumin and crystalloids is restraining the adoption of HES, especially in developed markets where healthcare systems are more regulated.

Opportunity:

1. Emerging Demand in Developing Countries:

In low- and middle-income countries, the need for affordable and efficient plasma expanders opens new opportunities for HES due to its lower cost compared to natural colloids.

2. Expansion of Surgical and ICU Infrastructure:

As hospitals expand their intensive care and surgical departments globally, the demand for intravenous fluids and colloid solutions like HES is expected to grow.

Market by System Type Insights:

Based on system type, Tetrastarch formulations accounted for the largest market share in 2023 due to their improved pharmacokinetics and lower side-effect profile compared to older variants like hetastarch and pentastarch. The tetrastarch segment is anticipated to witness the highest growth during the forecast period as it becomes the preferred choice in many clinical protocols.

Market by End-Use Insights:

By end use, Hospitals dominated the market in 2023, accounting for over 60% of the total revenue. Their extensive usage of HES in surgeries, ICUs, and emergency rooms positions them as the largest consumers. Ambulatory Surgical Centers (ASCs) are expected to witness rapid growth owing to the rise in outpatient surgical procedures globally.

Market by Regional Insights:

Geographically, North America held the largest market share in 2023 due to the presence of leading pharmaceutical companies, high surgical volumes, and robust healthcare infrastructure. However, Asia-Pacific is projected to be the fastest-growing region, driven by increasing healthcare investments, rising population, and a higher burden of surgical and trauma-related cases.

Competitive Scenario:

Key players operating in the Global Hydroxyethyl Starch Market include:

Fresenius Kabi AG

B. Braun Melsungen AG

Pfizer Inc.

ICU Medical Inc.

Baxter International Inc.

Grifols, S.A.

Jiangsu Hengrui Medicine Co., Ltd.

These companies focus on R&D, regulatory compliance, and strategic partnerships to enhance their market presence. For instance:

In 2023, B. Braun expanded its manufacturing unit in Asia to increase production capacity of hydroxyethyl starch solutions.

Fresenius Kabi launched a new generation of tetrastarch products in European markets in 2022, aligning with updated safety guidelines.

Scope of Work – Global Hydroxyethyl Starch Market

Report Metric Details

Market Size (2023) USD 505 million

Projected Market Size (2031) USD 792 million

CAGR (2023–2031) 5.8%

Market Segments By System Type (Tetrastarch, Pentastarch, Hetastarch), By End-use, By Region

Growth Drivers Rise in surgeries, increasing demand for plasma expanders, innovation in formulations

Opportunities Emerging markets, expanding critical care infrastructure

Key Market Developments:

2023: Fresenius Kabi initiated clinical trials for next-generation HES solutions aimed at reducing adverse renal effects.

2022: ICU Medical completed acquisition of a regional HES manufacturer to boost product availability in Latin America.

2021: Baxter International introduced a hybrid plasma expander combining tetrastarch with electrolytic balance enhancers.

FAQs:

1. What is the current market size of the Global Hydroxyethyl Starch Market?

The market size in 2023 was valued at USD 505 million.

2. What is the major growth driver of the Global Hydroxyethyl Starch Market?

The key driver is the increasing number of surgeries and trauma cases requiring plasma volume expansion.

3. Which is the largest region during the forecast period in the Global Hydroxyethyl Starch Market?

North America is expected to dominate, while Asia-Pacific shows the highest growth rate.

4. Which segment accounted for the largest market share in the Global Hydroxyethyl Starch Market?

The Tetrastarch segment led the market in 2023.

5. Who are the key market players in the Global Hydroxyethyl Starch Market?

Leading players include Fresenius Kabi AG, B. Braun Melsungen AG, Pfizer Inc., and Baxter International Inc.